Abstract Prostate Cancer (PCa) is the second leading cause of cancer-related death in men.
Adenocarcinoma of the prostate is primarily composed of Androgen Receptor-positive (AR+) …

Prostate carcinoma (PCa) displays a wide variety of genetic alterations, versatile expression
profiles as well as cell surface markers. Despite this heterogeneity, a common treatment for …

Androgen receptor splicing variants (ARVs) that lack the ligand-binding domain (LBD) are
associated with the development of castration-resistant prostate cancer (CRPC), including …

Prostate cancers that progress during androgen-deprivation therapy often overexpress the
androgen receptor (AR) and depend on AR signaling for growth. In most cases, increased …

Typically, the initial response of a prostate cancer patient to androgen ablation therapy is
regression of the disease. However, the tumor will progress to an “androgen-independent” …

Background: Cell line models suggest that activation of NFκB is associated with progression
of prostate cancer. This pathway may be a therapeutic target if these observations translate …

Resistance of prostate cancer cells to the next-generation antiandrogen enzalutamide may
be mediated by a multitude of survival signaling pathways. In this study, we tested whether …

Prostate cancer is a highly prevalent form of cancer that is usually slow-developing and
benign. Due to its high prevalence, it is, however, still the second most common cause of …

Castration-resistant prostate cancer (CRPC) remains dependent on androgen receptor (AR)
signaling. Alternative splicing of the AR to generate constitutively active, ligand-independent …

Rel/NF-ΚB transcription factors are key regulators of genes implicated in inflammatory and
immune activation, cell growth and protection from apoptosis. Constitutive activation of NF …